$250MGrowth, 7 May 2026
Funds support development, approval and launch of ANG003 for exocrine pancreatic insufficiency, including in cystic fibrosis.
- Amount
- $250M
- Stage
- Growth
- Announced
- 7 May 2026
- Lead
- Blackstone Life Sciences
- Use of funds
- Funds support development, approval and launch of ANG003 for exocrine pancreatic insufficiency, including in cystic fibrosis.
- Checked
- Announced by the company
- Sources
- Anagram Therapeutics raises $250M from Blackstone Life Sciences businesswire.com
Anagram Therapeutics raises $250M from Blackstone Life Sciences pulse2.com